SCHEMBL980240

SCHEMBL980240

Cc1ccc(C2=NN(C(=O)Cc3ccccc3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.53
PGR P06401 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 1/20 0.51
RAB9A P51151 1/20 0.51
GAA P10253 2/20 0.49
PKM P14618 1/20 0.49
LMNA P02545 1/20 0.49
KDM4E B2RXH2 2/20 0.48
F2 P00734 1/20 0.48
POLB P06746 1/20 0.48
HCRTR1 O43613 1/20 0.47
TP53 P04637 2/20 0.47
GPR183 P32249 1/20 0.46
MAPT P10636 1/20 0.44
ORAI1 Q96D31 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CASP3 P42574 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981651 0.90 ALDH1A1 (0.50) PGRSMN1; SMN2ALDH1A1HPGDRAB9A
SCHEMBL982174 0.87 MAOB (0.51) MAOBPGRSMN1; SMN2ALDH1A1HPGD
SCHEMBL12922889 0.87 MAOB (0.50) MAOBPGRSMN1; SMN2ALDH1A1HPGD
SCHEMBL979242 0.87 ALDH1A1 (0.56) PGRSMN1; SMN2ALDH1A1HPGDRAB9A
SCHEMBL981780 0.86 ALDH1A1 (0.48) PGRSMN1; SMN2ALDH1A1HPGDRAB9A
SCHEMBL979286 0.86 ALDH1A1 (0.71) MAOBSMN1; SMN2ALDH1A1HPGDRAB9A
SCHEMBL982974 0.84 RAB9A (0.58) MAOBSMN1; SMN2ALDH1A1HPGDRAB9A
SCHEMBL981338 0.84 ALDH1A1 (0.58) MAOBSMN1; SMN2ALDH1A1HPGDRAB9A
SCHEMBL982457 0.83 MAOB (0.49) MAOBPGRSMN1; SMN2ALDH1A1HPGD
SCHEMBL982270 0.82 SMN1; SMN2 (0.52) MAOBSMN1; SMN2ALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 MAOB 1138/4885PGR 1338/4885SMN1; SMN2 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.